Kornimate/medical-research-clean huggingface dataset:
ilomedin treatment for patients having undergone primary percutaneous coronary intervention (pci)

Conditions: Myocardial Infarct

Summary: acute myocardial infarct patients with stemi (st-elevation on ecg) whom undergo a primary percutaneous cardiac intervention will following the standard treatment , received low dose of ilomedin and to low dose of standard treatment for another 24 hours.


Eligibility criteria:
inclusion criteria: 1. age \> 18 years 2. undergoing primary pci due to stemi (timi flow i -iii before pci and symptom duration \< 12 hours) 6) following receipt of verbal and written information about the study, the patient must provide signed informed consent before any study data is used. - exclusion criteria: 2) not able to give informed consent 3) women with childbearing potential 4) on-going concomitant treatment with k-vitamin antagonists (one bolus dose pre-pci allowed) 5) known congenital or acquired coagulopathy and/or thrombocytopathy s 8) participation in a clinical study and/or another investigational device within the past four weeks prior to day 1 9) major surgery or trauma within the past 6 weeks prior to day 1 10) a blood coagulation disorder (i.e. international normalized ratio \[inr\] \> 2.0, platelet count \ 140 mmol/l) 12) major procedure related bleeding (timi major criteria); gi or urinary tract bleeding prior to inclusion in the trial 13) known active hepatitis b and/or hepatitis c or hiv 14) known or suspected hypersensitivity to components of the investigational medicinal product -

Keywords: st-eleveation myocardial infarct percutaneous coronary intervention myocardial infarct stemi patients
evaluation of new biomarkers of thrombosis in myeloproliferative neoplasms

Conditions: Myeloproliferative Neoplasm

Summary: thrombosis is the main cause of morbidity and mortality in patients with myeloproliferative neoplasms (mpn). however, the pathogenesis of thrombosis in mpn is still largely elusive. neutrophils can release their decondensed chromatin as a network of extracellular fibers named net for "neutrophils extracellular trap". nets are known to be procoagulant. our main objective is to quantify nets biomarkers expression in mpn patients and define if they could be used as prognostic factors in the outcome of thrombosis in these patients.

myeloproliferative neoplasms (mpn) are acquired clonal hematopoietic stem cell disorders, characterized by an increase in one or more myeloid lineages. the philadelphia chromosome negative (ph-) mpn include polycythemia vera (pv) with an excess of red blood cells, essential thrombocythemia (et) with an increase in platelets and primary myelofibrosis (pmf). arterial and venous thromboses are the main causes of morbidity and mortality in mpn with reported incidences ranging from 12-39% in pv and 11-25% in et. the pathogenesis of thrombosis in mpn patients is complex and still largely elusive. the overproduction of neutrophils could be an important risk factor in the thrombus formation. indeed neutrophils are known to promote thrombosis when they release their decondensed chromatin as a network of extracellular fibers named net for "neutrophils extracellular trap". increased netosis has been reported in a mouse model of mpn. the main objective of this study is to investigate whether net biomarkers are associated with increased thrombotic risk in patients with et. indeed, an international thrombotic prognostic score has been published in et, ie the ipset thrombosis score (history of thrombosis, age, presence of jak2v617f, cardiovascular risk factors). plasma from mpn patients will be collected, at the time of diagnosis, and measure markers of neutrophil activation, including net biomarkers. the ipset thrombosis score will be evaluated in patients with et and the correlation between the ipset thrombosis score and these biomarkers will be measured. no follow-up is required for this study.

Eligibility criteria:
inclusion criteria: * adults (age ≥18 years), * patients diagnosed with polycythemia vera (pv) or essential thrombocythemia (et) according to who 2008 criteria, * affiliated to the national social security system, * signed informed consent form will be required for each included subject after having read the information note, * patient agreeing to be included in the fimbank register and having signed the corresponding consent exclusion criteria: * adults (age \>18 years), male or female, * patients treated with heparin or undergoing cytoreductive treatment, * pregnant or lactating woman, * person under guardianship, tutorship or other legal protection scheme or incapable of giving consent

Keywords: polycythemia vera (pv) essential thrombocythemia (et) neutrophil extracellular trap (net) thrombosis
measurement of the electromechanical window to improve the diagnosis of congenital long qt syndrome

Conditions: Long QT Syndrome

Summary: the goal of this research is to prospectively evaluate the performance of the electromechanical window according to a phonographic method, as a mean of diagnosis of long qt syndrome, and to compare its performance with routine tests used.

familial long qt syndrome (lqts) is a hereditary cardiac disorder in which most affected family members have delayed ventricular repolarization manifest on the electrocardiogram (ecg) as qt prolongation. this disease is associated with an increased propensity to palpitations, syncope, polymorphous ventricular tachycardia and sudden arrhythmic death. the diagnosis relies mostly on resting ecg findings and on genetic testing. in clinical practice however, this diagnosis is complicated by 2 main reasons: 1) a significant overlap in ecg findings between healthy and diseased individuals and 2) a frequent identification of genetic variants of unknown significance. recent studies have suggested that echocardiographic measurement of the electromechanical window (emw - the delay between the end of mechanical contraction and electrical activation of the heart) has better performance in the diagnosis of lqts. the echocardiographic technique is however too complicated for routine clinical use. preliminary work conducted at the university hospital of bordeaux and at the university hospital of reunion island has demonstrated that a phonocardiographic approach leads to similar results with an improved feasibility and a good reproducibility.

Eligibility criteria:
inclusion criteria: * propositus patients with genetically proven lqts and their relatives, * patients of both sexes aged 12 and over, * free, informed and written consent of the patient and the two holders of parental authority for minors. exclusion criteria: * inability to consent, * person deprived of liberty by judicial or administrative decision, * majors subject to a legal protection measure, * person participating in another research including an exclusion period still in progress, * severely impaired physical and / or psychological health, which, according to the investigator, may affect the participant's compliance with the study.

Keywords: long qt syndrome electromechanical window phonocardiography
effects of kinesio-taping and muscle energy technique on chronic sacroiliac joint dysfunction

Conditions: Musculoskeletal Injury

Summary: pregnancy is the main occasion of every woman's life in which numerous episodes of physiological and anatomical adjustments takes place within woman's body to become a mother. anatomical changes often leads to poor biomechanics and may cause mechanical dysfunction of spine especially lower back.. sacroiliac joint (sij) goes through most of mobility during the period of pregnancy due to hormone release causes ligamentous laxity that can cause sijd.

fifty two patients will be randomly divided into two groups i.e. group-a (n=26) and b (n=26) respectively through simple random sampling, sealed envelope method. informed consent will be taken from the participant prior to intervention. baseline assessment will be carried out before the first session of all the recruited participants on four outcome measures using, patrick's faber test for provocation of pain, nprs for intensity of pain, rmdq for physical disability and palm pelvic inclinometer for pelvic asymmetry respectively. skin reaction test will be conducted before randomization after the baseline assessment for all participants. a small patch of kinesio tape will be applied to the hip region and the participants will be asked to keep it for 24 hours. if any of the participants will develop allergic reaction, it will be removed immediately and participants with positive results will be excluded from the study. after this test, the allergy-free patients will be randomized into 2 groups for treatment. participants of group-a will be applied kt with conventional physiotherapy while group-b participants will perform met with conventional physiotherapy. whereas, both the groups will be given 12 sessions of their respective protocol, comprising 20 minutes, 3 times/week for the duration of 4 weeks. after the end of the intervention, subjects will be reassessed after the last session and data will be collected on the same outcome measures for further evaluation

Eligibility criteria:
inclusion criteria: * postpartum with diagnosed cases of sijd dysfunction (after 3 months of delivery) with age range between 20 to 35 years * postpartum with unilateral/bilateral both sijd * postpartum with anterior innominate exclusion criteria: * history of any fracture at lower limb in recent 6 months * pregnant females * spinal stenosis, spondylolisthesis * malignancy of spine or lower limb * radiculopathy * conditions like diastasis recti, prolapse pelvic organ * history of recent infection

Keywords: sacroiliac joint exercise muscle energy technique
prevalence and risk factors for pelvic floor disorders

Conditions: Pelvic Floor Disorders

Summary: pelvic floor disorders (pfd) can adversely affect the quality of life of a woman and they can occur during different stages of female life such as during pregnancy, early postpartum period or during menopause. it is well known that pregnancy and vaginal birth are significant risk factors in the etiology of pfd and predicting models like ur-choice score were developed for this reason to provide mothers-to-be with sufficient information regarding their subsequent risk of pfd. pregnancy, childbirth and the immediate postpartum period, where the demands on the pelvic floor and the incidence of pelvic floor trauma are particularly high, offers an optimal opportunity for such counseling and prevention.

pelvic floor disorders (pfds) can adversely affect the quality of life (qol) of a woman and they can occur during different stages of female life such as during pregnancy, early postpartum period or during menopause. the reported prevalence of pfds varies widely both during and after pregnancy and reported up to 30-50%. besides, the term pfd includes a broad spectrum of conditions such as urinary incontinence (ui), pelvic organ prolapse (pop) or anal incontinence (ai). many risk factors seem to be involved like the pregnancy itself, mode of delivery, parity, the use of episiotomy, obesity, increased age and so on. it is well known that pregnancy and vaginal birth are significant risk factors in the etiology of pfds and predicting models like ur-choice score were developed for this reason to provide mothers-to-be with sufficient information regarding their subsequent risk of pfd. the identification of women during their pregnancy who are at higher risk for pfd remains a key element in targeting of prevention and planning health of resource allocation strategies. pregnancy, childbirth and the immediate postpartum period, where the demands on the pelvic floor and the incidence of pelvic floor trauma are particularly high, offers an optimal opportunity for such counseling and prevention. the validated german pelvic floor questionnaire modified for pregnancy and postpartum period is thus an important tool identifying such symptoms and helping clinicians assess patient's quality of life. the aim of the present study was to evaluate the prevalence of pfds in a cohort of egyptian women during pregnancy. furthermore, we searched for clinical risk factors that correlate with the occurrence of pfds during pregnancy in the investigator's population.

Eligibility criteria:
inclusion criteria: * age over 18 years * any trimester of pregnancy * planned delivery at our institution. exclusion criteria: * women with the inability to complete the questionnaire
study to compare double-dose betaferon to the approved dose, for patients with early secondary progressive multiple sclerosis (spms)

Conditions: Multiple Sclerosis

Summary: the purpose of the study is to evaluate if the higher dose can give greater efficacy without negative impact on the adverse event profile for patients with early secondary progressive multiple sclerosis (spms).

the study has previously been posted by schering ag, germany. schering ag, germany has been renamed to bayer schering pharma ag, germany. bayer schering pharma ag, germany is the sponsor of the trial.

Eligibility criteria:
inclusion criteria: * diagnosis of ms for no less than one year and no longer than ten years * disease in the secondary progressive (sp) phase * at least one relapse the last 3 years * treatment with an interferon for at least 6 months and with betaferon for at least 3 months exclusion criteria: * serious or acute heart disease * severe depression * serious or acute liver, kidney or bone marrow dysfunction * epilepsy not adequately treated * pregnancy or lactation * alcohol or drug abuse

Keywords: multiple sclerosis early secondary progressive multiple sclerosis
prosthetic rehabilitation of thin wiry ridge by ridge splitting and simultaneous implants placement

Conditions: Atrophic Maxillary Ridge and Mandibular Ridge

Summary: evaluates the success of prosthetic rehabilitation of thin wiry ridge and implants placed simultaneously in splitted ridge both clinically and radiographically.

twenty-one participants were enrolled of which 13 patients (8 females and 5 males) were suffering from maxillary ridge atrophy and 8 patients (5 females and 3 males) had mandibular ridge atrophy; a total of 42 implants were performed using the ridge expansion technique. the expansion was performed using the conventional disk technique, piezoelectric corticotomy, and self-threading expanders. implants were placed and loaded with fixed partial denture after 4 months for the mandible and 6 months for the maxilla. implant stability quotient (isq) was measured at t0 (implant placement) and tl (loading). crestal bone levels were measured at different times: t0, tl, and t12 (12 months). evaluation of prosthetic and surgical complications was carried out. data were analyzed and compared using analysis of variance and paired t-tests at a significance level of 5%.

Eligibility criteria:
inclusion criteria: * ridge of 2 to 4 mm of initial alveolar crest width * bone height of at least 8 mm from vitastructures good oral hygiene. exclusion criteria: patients who smoke more than 10 cigarettes per day diabetes mellitus, osteoporosis, and periodontal disease.

Keywords: implant knife-edge ridge ridge expansion piezoelectric implant-supported prosthesis prosthetic complications
cns changes following stroke

Conditions: Stroke

Summary: the objective of this study is to better understand the structural and functional changes that the cns undergoes following stroke and how these changes relate to clinical measures. both macroscopic and microscopic changes of the brain and the spinal cord will be examined in stroke patients and compared to healthy controls. in terms of structural plasticity, we aim to identify mr biomarkers that allow predicting the course of the patient's neurological status and accurately describe the course of the disease and the recovery. importantly, we aim to investigate which factors scale the patients' symptoms. in terms of functional plasticity, we will combine fmri with behavioural motor and sensory testing to understand i) the structural and functional interplay between spinal and supraspinal neural circuits after stroke possibly driven by beneficial plasticity/regeneration vs. maladaptive plasticity/degeneration and ii) which clinical and behavioural determinants drive functional hand representations in the primary somatosensory and motor cortices to be maintained and which determinants drive reorganisation of functional representations following sensory input loss. we will further investigate the contribution of brainstem reorganisation to plasticity observed at the cortical level and, by doing so, aim to better understand the mechanistic underpinnings of functional reorganisation.


Eligibility criteria:
inclusion criteria - patients: * age 18-80 * stroke (\> 3months) * signed informed consent exclusion criteria - patients: * contraindications to magnetic resonance imaging * neurological impairment of body function impairments not induced by stroke * bmi \> 40 * pregnancy * claustrophobia inclusion criteria - healthy subjects: * age 18-80 * signed informed consent exclusion criteria - healthy subjects: * contraindications to magnetic resonance imaging * pregnancy * neurological illness * impairment of body function induced by stroke * claustrophobia * bmi \>40
a study evaluating oral eluxadoline administered to pediatric participants with irritable bowel syndrome with diarrhea (ibs-d)

Conditions: Irritable Bowel Syndrome

Summary: this study will assess the long-term safety of oral eluxadoline administered to pediatric participants with ibs-d who have completed study intervention in the phase 2 study 3030-202-002 or the phase 3 study 3030-303-002.


Eligibility criteria:
inclusion criteria: inclusion criteria: * male or female participants must be 6 to 17 years of age (inclusive) * participants must have completed study intervention in their lead-in study exclusion criteria: * participant has an unresolved ae or a clinically significant finding on a physical examination, vital sign assessment, or neurological assessment along with an ecg or clinical laboratory tests (if results are available by the time of enrollment) that; in the opinion of the investigator, could represent a safety concern or a condition that would be exclusionary, could prevent the participant from performing any protocol assessments, or could confound study assessments. * participant has known allergies or hypersensitivity to opioids * female participants who are currently pregnant or nursing, or plan to become pregnant or nurse during the clinical study. * participant has no gallbladder, (ie, agenesis of the gallbladder or cholecystectomy). * participant has known or suspected biliary duct obstruction, or sphincter of oddi disease or dysfunction * participant has a history of pancreatitis; structural diseases of the pancreas, known or suspected pancreatic duct obstruction * participant has a history of chronic or severe constipation, or sequelae from constipation, or known or suspected mechanical gi obstruction or pseudo obstruction * participant has renal impairment or an unstable hepatic, metabolic, or hematologic condition. * participant is a current regular alcohol drinker and/or binge drinker\*, and/or has a history of alcoholism, alcohol abuse (eg, binge-drinking\*), or alcohol addiction, and/or intends to consume alcohol during the study

Keywords: irritable bowel syndrome with diarrhea ibsd ibs-d irritable bowel syndrome pediatric
enhancing cognitive and neurobehavioral functions after repetitive traumatic brain injuries (rtbi) in retired nfl players and military veterans.

Conditions: Traumatic Brain Injury; Concussion; Mild Cognitive Disorder

Summary: the purpose of this study is to compare different combinations of cognitive training in retired professional football players and military veterans with a history of repeated concussions and persistent symptoms of impaired memory, concentration, attention, focus, or thinking.


Eligibility criteria:
inclusion criteria: * history of \>1 mild tbi: post traumatic amnesia/confusion ≤ 24 hour immediately after injury; or loss of consciousness \<30 min confirmed by the ohio state university tbi identification method-short form (osu tbi-id-sf). * age 25-55 years * minimum of 4 months post-injury * adequate visual, auditory, sensory-motor function for training program. * fluent in english * persistent cognitive dysfunction confirmed by ruff neurobehavioral inventory score of greater than 70 on any of the four cognitive scales (attention, memory, language, executive). exclusion criteria: * history of hypoxic event * pre-existing significant neurological (e.g. ms) or psychiatric (e.g. schizophrenia, bi-polar) disorders. * current illicit drug use or alcohol abuse * unwilling or unable (e.g. language barrier) to participate * hospitalization during study * current litigation * positive on malingering test * use of medications to enhance cognitive function (e.g. ritalin) * initial glasgow coma score \< 13 or penetrating head injury * subjects must not show suicidal ideation as measured by the columbia-suicide severity rating scale. subjects with a score of 4 or 5 (as recommended by the fda for treatment trials) will be excluded and referred for appropriate treatment. * subjects should not be enrolled in a concurrent tbi clinical trial.

Keywords: nfl veterans cognitive training tbi concussion
dalteparin low molecular weight heparin for primary prophylaxis of venous thromboembolism in brain tumour patients

Conditions: Venous Thromboembolism; Brain Tumors

Summary: in patients with malignant glioma, to determine the efficacy of prophylaxis with lmwh (dalteparin) compared to placebo, both commenced beyond the immediate postoperative period, for the prevention of vte.

patients are randomized 1:1 to receive dalteparin 5,000 anti-xa units s.c. daily versus placebo s.c. daily. the primary outcome is vte-free survival at 6 months. progression free survival; overall survival, toxicity, and neurocognitive performance are secondary outcome measures.

Eligibility criteria:
inclusion criteria: * both of the following criteria must be satisfied: 1. patients with newly-diagnosed pathologically-confirmed who grade 3 or grade 4 glioma (anaplastic astrocytoma, glioblastoma multiforme, gliosarcoma, anaplastic oligodendroglioma, and anaplastic mixed glioma). tumour histology is based on local pathology review only; 2. patients 18 years of age or older at time of randomization exclusion criteria: * if one or more of the following criteria are satisfied, the patient is not eligible for the study: 1. the presence of acute or chronic dvt demonstrated by duplex ultrasonography (dus) or venography. (note: a screening dus is not required for study entry); 2. inability to commence study drug within four weeks of original surgery or biopsy; 3. serious hemorrhage requiring hospitalization, transfusion, or surgical intervention within four weeks of potential study entry; 4. presence of a coagulopathy (e.g. inr \>1.5 or platelet count \< 100x109/l); 5. symptomatic intracranial or intratumoural bleeding. (note: post-operative imaging of the brain is not required for study entry. asymptomatic "routine" post-operative blood products in a post-surgical cavity are not an exclusion; 6. known acute (symptomatic or actively bleeding) gastroduodenal ulcer; 7. familial bleeding diathesis; 8. requiring long term anticoagulants for other reasons (e.g., mechanical heart valves, atrial fibrillation); 9. uncontrolled hypertension despite antihypertensive therapy; 10. significant renal failure (dependent on dialysis or creatinine of greater than three times upper limit of normal control); 11. prior history of documented dvt or pe; 12. allergy to anticoagulants (ufh, lmwh) including immune-mediated heparin-induced thrombocytopenia; 13. pregnant or of childbearing potential and not using adequate contraception; 14. geographically inaccessible for follow-up; 15. having an expected life span of less than 6 months; 16. body weight \< 40 kg.

Keywords: deep vein thrombosis pulmonary embolism glioma fragmin anticoagulant prophylaxis dalteparin